



## What can the conect4children Stichting (c4c-S) do for ERNs?

conect4children Stichting (c4c-S) links industry and academic investigators with sites and experts using processes tried and tested in more than 50 engagements. c4c-S is an independent non-profit Foundation based in the Netherlands that aims to promote the availability of medicines, and other forms of treatment and prevention, to the paediatric population through efficient clinical research. A Single Point of Contact (SPoC) receives requests from industry and academic investigators.

Expert advice about all aspects of clinical paediatric drug development is available covering methodology and clinical topics. This provides state of the art input to protocols and development plans based on contributions from more than 400 experts. Input from children, young people and their families can be included in services. The experts have all signed Agreements with c4c-S. Advisory Boards can be identified within a couple of weeks of contract execution and a full report is typically delivered within 3 months of contract execution.

Trial support services include: a) site identification; b) protocol-driven feasibility assessment; c) support for sites during trial setup and conduct. Site identification draws on more than 250 research-ready sites across Europe including sites within European Reference Networks (ERNs) and sites not included in ERNs. This service typically providing a long list of sites within 2 weeks of contract execution. Feasibility assessment is done under Confidentiality Disclosure Agreements (CDAs) that are typically signed within 2 weeks of contract execution with c4c-S. Detailed feasibility reports are provided within 6 weeks of contract execution with c4c-S. Site identification and feasibility are mediated by National Hubs (NH) that bring country-specific insights. NHs are well-positioned to support sites during trial setup and conduct through long-term relationships that supplement trial-specific relationships with industry and academic investigators.

During 2023-2024 the c4c network was involved in more than 40 Expert Advice engagements and 15 Trial Support engagements. More than half of these engagements involve a rare disease, including collaborations with ERNs. c4c-S is the main Result of a successful Public Private Partnership designed to setup a sustainable legal entity that makes it easier to do paediatric drug development in Europe. The Innovative Medicines Initiative 2-funded project co-developed services with industry and academia. These services are now available to the whole life sciences sector and are relevant from the start of planning for paediatric development until closure of clinical studies.

Please contact [c4c.spoc@conect4children.eu](mailto:c4c.spoc@conect4children.eu) for more information or to discuss how c4c-S can help you. A flyer about Expert Advice is available here: [https://conect4children.eu/wp-content/uploads/2024/03/C4C\\_Flyer\\_Expert\\_Advice\\_v1.7.pdf](https://conect4children.eu/wp-content/uploads/2024/03/C4C_Flyer_Expert_Advice_v1.7.pdf)

A flyer about Trial Support is available here: [https://conect4children.eu/wp-content/uploads/2024/03/C4C\\_Flyer\\_Site\\_Identification\\_v1.7.pdf](https://conect4children.eu/wp-content/uploads/2024/03/C4C_Flyer_Site_Identification_v1.7.pdf)

The website is here: <https://conect4children.eu>